Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

s was $22.4 million for the quarter ended September 30, 2009 compared to $58.7 million for the same period in 2008. Net loss for the quarter ended September 30, 2009 was $26.7 million, or $0.19 per share, compared to $79.0 million, or $0.58 per share, for the same period in 2008.

"The third quarter was one of strong operational and financial results and positions us well for long-term growth," said Daniel M. Bradbury, president and chief executive officer at Amylin Pharmaceuticals. "We continue to execute on our growth strategy by making progress against our long-term commercial plans, maximizing the potential of our clinical programs and advancing our pipeline."

Third Quarter Highlights

Highlights of Amylin's third quarter and recent activities include:

Corporate

  • Improved non-GAAP operating loss by 64% in the first nine months of 2009 compared to the same period in 2008
  • Entered a Global Development and Commercialization Agreement with Biocon Limited for a novel peptide hybrid
  • Announced Paulo F. Costa as Amylin's Chairman of the Board

Exenatide

  • Received the Day 74 letter from the U.S. Food and Drug Administration (FDA) and submitted the 120 day safety update for exenatide once weekly
  • Presented data from more than 20 studies, with partner Eli Lilly and Company, at the Annual Meeting of the European Association for the Study of Diabetes (EASD). Data presented were the latest research findings on BYETTA and exenatide once weekly

Nine Months Ended September 30, 2009

Total revenues for the nine months ended September 30, 2009 were $614.3 million. This includes net product sales of $569.7 million, including $503.9 million for BYETTA and $65.8 million for SYMLIN. This compares to net product sales of $580.4 million, consisting of $515.9 million for BYETTA and $64.5 million for SYMLIN for the same period in
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... FREMONT, Calif. , May 5, 2015 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and ... 2a clinical trial evaluating tenapanor in Stage 3 ... mellitus and albuminuria did not meet the primary ... tenapanor-treated patients compared to patients receiving placebo. ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - ... Laval and known under the « ... the closing of the transaction previously announced on April ... issued and outstanding  shares of Orthoconcept (2008) inc.   ... 500 000 common shares (TSXV: ERG) to the vending ...
(Date:5/5/2015)... -- The preclinical contract research organization Absorption Systems , ... safety testing of medical devices, announces that Dr. ... at this week,s annual meeting of The Association for ... Denver, CO. The title of Dr. Gum,s ... Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer in a Rabbit ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... aureus and, Methicillin-Resistant Staphylococcus aureus from Positive ... BD Diagnostics, a segment,of BD (Becton, Dickinson and ... it,received clearance from the U.S. Food and Drug ... new assay is the first test available to,rapidly ...
... Dec. 27 Allos,Therapeutics, Inc. (Nasdaq: ALTH ... (DMC) has completed the pre-specified 65-patient,safety review of ... trial of,PDX (pralatrexate) in patients with relapsed or ... the trial continue per the,protocol. This interim assessment ...
Cached Medicine Technology:BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 2BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:5/5/2015)... With the FCPX LUT: Monochromatic pack from Pixel ... color grades to footage. A LUT is a Lookup Table ... LUT changes every pixel's color to the corresponding color indicated ... LUT files. , This plugin was inspired by indie films ... washed look. , CUBE LUT files are extremely versatile. ...
(Date:5/5/2015)... Indian Trail, NC (PRWEB) May 05, 2015 ... firm serving Indian Trail, Monroe, Matthews, Charlotte and surrounding ... in the field of accounting. This company provides assistance ... a priority as they prepare individual or corporate tax ... a system in the cloud that allows clients (and ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Health IVF Clinic in Greece, an experienced team ... and treatment of infertility for patients around the globe. ... partnered with VisitandCare.com. Greece unquestionably remains a global leader ... most talented and hard-working fertility specialists in the world ...
(Date:5/5/2015)... 2015 From the halls of ... leader in enabling enterprise collaboration across platforms and ... speed up and simplify the move to Microsoft ... Solutions for Office 365 enable organizations to ... sustainable user adoption and effectively managing critical business ...
(Date:5/5/2015)... Dr. Patricia George knows all too well the ... pulmonary hypertension specialist at the University of Pittsburgh Medical ... an initial idea entered her mind for Team PHenomenal ... at the 2010 PHA International Conference,” George recalled. “The ... recalling their climb up Mt. Kilimanjaro and I remember ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2
... point out , , TUESDAY, Dec. 2 (HealthDay News) -- A ... wallets but on their health as well, a new survey ... to costs, according to a Harris Interactive poll released Tuesday ... U.S. Department of Health and Human Services. , That means ...
... A long history of terrorism in India precedes the ... (GTD), maintained at the University of Maryland by the ... to Terrorism (START) counts more than 4,100 terrorist attacks ... This information is freely available online. , The GTD ...
... News/ -- EIN News has announced the launch of a new ... , With new advances in medicine, more and ... key components to surviving cancer. , ... about prostate cancer, its risk factors, screening procedures and drugs to ...
... Colo., Dec. 2 MicroPhage, Inc., http://www.microphage.com , announced ... Board of Directors. Taussig was president and CEO ... nation,s leading institution,for studying respiratory diseases, from 1993 to ... "I have followed MicroPhage ...
... worldwide leader in the,development, distribution and use of minimally ... of India HIFU and,the launch of Sonablate(R) HIFU services ... treatment of prostate disease. , ... Nephrology Services at the,hospital said, "The introduction of the ...
... T Zone? It is the mucous membranes of your eyes, nose ... enter your body and grow to make you sick. Touching ... contamination, eye rubbing, nose picking, nail biting and many other descriptors. ... help reduce flu and flu-like illness this winter. It is ...
Cached Medicine News:Health News:Economy Driving Women to Skimp on Health Care: Poll 2Health News:Economy Driving Women to Skimp on Health Care: Poll 3Health News:India terrorism by the numbers 2Health News:EIN News Introduces 'Prostate Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:MicroPhage Selects Lynn Taussig, MD for Board of Directors 2Health News:USHIFU Announces First Sonablate(R) HIFU Device in India for Minimally Invasive Prostate Cancer Treatment 2Health News:Dr. Will Sawyer and Henry the Hand Champion Handwasher Have Discovered How to PREVENT the Flu and Common Cold!! DO NOT TOUCH the T Zone! 2
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
The ToxCup Drug Screen Cup is a one-step test for the rapid detection of up to five drugs of abuse and four adulteration tests. It's design integrates sample collection, drug/adulteration testing and...
Lasts up to 3 months , Absorbable copolymer of glycolic acid and trimethylene carbonate , Designed to provide relief from short term dry eye conditions. , Appropriate for surgery-related d...
... transconjunctival self-retaining infusion cannulas for use in ... some benefit to patients that present with ... lessening the occurrence of suture induced astigmatism. ... and does not require a blade for ...
Medicine Products: